Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.

Devarakonda S, Rotolo F, Tsao MS, Lanc I, Brambilla E, Masood A, Olaussen KA, Fulton R, Sakashita S, McLeer-Florin A, Ding K, Le Teuff G, Shepherd FA, Pignon JP, Graziano SL, Kratzke R, Soria JC, Seymour L, Govindan R, Michiels S.

J Clin Oncol. 2018 Aug 14:JCO2018781963. doi: 10.1200/JCO.2018.78.1963. [Epub ahead of print]

PMID:
30106638
2.

Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer.

Rotolo F, Zhu CQ, Brambilla E, Graziano SL, Olaussen K, Le-Chevalier T, Pignon JP, Kratzke R, Soria JC, Shepherd FA, Seymour L, Michiels S, Tsao MS.

Transl Lung Cancer Res. 2018 Jun;7(3):416-427. doi: 10.21037/tlcr.2018.05.01.

3.

Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial.

Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH; ECOG-ACRIN.

Lancet Oncol. 2017 Dec;18(12):1610-1623. doi: 10.1016/S1470-2045(17)30691-5. Epub 2017 Nov 9.

PMID:
29129443
4.

Subtype Classification of Lung Adenocarcinoma Predicts Benefit From Adjuvant Chemotherapy in Patients Undergoing Complete Resection.

Tsao MS, Marguet S, Le Teuff G, Lantuejoul S, Shepherd FA, Seymour L, Kratzke R, Graziano SL, Popper HH, Rosell R, Douillard JY, Le-Chevalier T, Pignon JP, Soria JC, Brambilla EM.

J Clin Oncol. 2015 Oct 20;33(30):3439-46. doi: 10.1200/JCO.2014.58.8335. Epub 2015 Apr 27.

5.

Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).

Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, Bogart J, Vokes EE.

J Clin Oncol. 2015 May 20;33(15):1660-5. doi: 10.1200/JCO.2014.57.3105. Epub 2015 Mar 2.

6.

Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA.

Graziano SL, Lacas B, Vollmer R, Kratzke R, Popper H, Filipits M, Seymour L, Shepherd FA, Rosell R, Veillard AS, Taron M, Pignon JP.

Lung Cancer. 2013 Oct;82(1):149-55. doi: 10.1016/j.lungcan.2013.06.015. Epub 2013 Aug 4.

7.

Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study.

Ready NE, Dudek AZ, Pang HH, Hodgson LD, Graziano SL, Green MR, Vokes EE.

J Clin Oncol. 2011 Nov 20;29(33):4436-41. doi: 10.1200/JCO.2011.35.6923. Epub 2011 Oct 3.

8.

Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633.

Graziano SL, Gu L, Wang X, Tatum AH, Vollmer RT, Strauss GM, Kratzke R, Dudek AZ, Vokes EE, Green MR; Cancer and Leukemia Group B; North Central Cancer Treatment Group; Radiation Therapy Oncology Group.

J Thorac Oncol. 2010 Jun;5(6):810-7.

9.

Methyldopa-induced autoimmune haemolytic anaemia revisited.

Thomas A, James BR, Graziano SL.

N Z Med J. 2009 Aug 21;122(1301):53-6.

PMID:
19829392
10.

PERMANENT GENETIC RESOURCES: Isolation and characterization of microsatellite loci from the Arctic cisco (Coregonus autumnalis).

Ramey A, Graziano SL, Nielsen JL.

Mol Ecol Resour. 2008 Mar;8(2):357-9. doi: 10.1111/j.1471-8286.2007.01955.x.

PMID:
21585791
11.

Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901.

Graziano SL, Herndon JE 2nd, Socinski MA, Wang X, Watson D, Vokes E, Green MR; Cancer and Leukemia Group B.

J Thorac Oncol. 2008 Feb;3(2):158-62. doi: 10.1097/JTO.0b013e318161225e.

12.

Acute coronary syndrome secondary to fluorouracil infusion.

Lu JI, Carhart RL, Graziano SL, Gajra A.

J Clin Oncol. 2006 Jun 20;24(18):2959-60. No abstract available.

PMID:
16782933
13.

CASE 2. Meningeal metastases from ovarian carcinoma.

Mukhopadhyay S, Mukhopadhyay S, El-Zammar O, Khurana KK, Graziano SL.

J Clin Oncol. 2006 Feb 20;24(6):1010-1. No abstract available.

PMID:
16484706
14.

Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730).

Lilenbaum RC, Herndon JE 2nd, List MA, Desch C, Watson DM, Miller AA, Graziano SL, Perry MC, Saville W, Chahinian P, Weeks JC, Holland JC, Green MR.

J Clin Oncol. 2005 Jan 1;23(1):190-6.

PMID:
15625373
15.

Prognostic markers in resected stage I and II non small-cell lung cancer: an analysis of 260 patients with 5 year follow-up.

Mehdi SA, Tatum AH, Newman NB, Gamble GP, Etzell JE, Weidner N, Kern JA, Sorscher SM, Kohman LJ, Graziano SL.

Clin Lung Cancer. 1999 Aug;1(1):59-67; discussion 68-9.

PMID:
14725752
16.

Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease.

Gajra A, Newman N, Gamble GP, Abraham NZ, Kohman LJ, Graziano SL.

Lung Cancer. 2003 Oct;42(1):51-7.

PMID:
14512187
17.

Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.

Vollmer RT, Govindan R, Graziano SL, Gamble G, Garst J, Kelley MJ, Christenson RH.

Clin Cancer Res. 2003 May;9(5):1728-33.

18.

Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer.

Gajra A, Newman N, Gamble GP, Kohman LJ, Graziano SL.

J Clin Oncol. 2003 Mar 15;21(6):1029-34.

PMID:
12637467
19.

Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer.

Johnson EA, Klimstra DS, Herndon JE 2nd, Catalano E, Canellos GP, Graziano SL, Kern JA, Green MR.

Cancer Invest. 2002;20(5-6):686-92.

PMID:
12197224
20.

The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer.

Gajra A, Tatum AH, Newman N, Gamble GP, Lichtenstein S, Rooney MT, Graziano SL.

Lung Cancer. 2002 May;36(2):159-65.

PMID:
11955650
21.

Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B.

Blackstock AW, Herndon JE 2nd, Paskett ED, Perry MC, Graziano SL, Muscato JJ, Kosty MP, Akerley WL, Holland J, Fleishman S, Green MR.

J Natl Cancer Inst. 2002 Feb 20;94(4):284-90.

PMID:
11854390
22.

Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study.

Graziano SL, Tatum A, Herndon JE 2nd, Box J, Memoli V, Green MR, Kern JA.

Lung Cancer. 2001 Aug-Sep;33(2-3):115-23.

PMID:
11551406
23.

Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.

Gajra A, Mehdi SA, Kirshner J, Newman N, Graziano SL.

Lung Cancer. 2001 May;32(2):189-96.

PMID:
11325490
24.

Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer.

Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, Khuri FR, Marks R, Winn RJ, Fry W, Graziano SL, Gandara DR, Okawara G, Woodhouse CL, Williams B, Perez C, Kim HW, Lotan R, Roth JA, Hong WK.

J Natl Cancer Inst. 2001 Apr 18;93(8):605-18.

PMID:
11309437
25.

Cryptic Mucor infection leading to massive cerebral infarction at initiation of antileukemic chemotherapy.

Mathur SC, Friedman HD, Kende AI, Davis RL, Graziano SL.

Ann Hematol. 1999 May;78(5):241-5.

PMID:
10391106
26.

Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer.

Graziano SL, Gamble GP, Newman NB, Abbott LZ, Rooney M, Mookherjee S, Lamb ML, Kohman LJ, Poiesz BJ.

J Clin Oncol. 1999 Feb;17(2):668-75.

PMID:
10080613
27.

Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study.

Graziano SL, Kern JA, Herndon JE, Tatum A, Brisson ML, Memoli V, Sugarbaker D, Skarin AT, Kreisman H, Green MR.

Lung Cancer. 1998 Sep;21(3):203-11.

PMID:
9857998
28.

Prognostic significance of Lewis y antigen in resected stage I and II non-small cell lung cancer.

Mehdi SA, Tatum AH, Newman NB, Imperato A, Daucher J, Kohman LJ, Graziano SL.

Chest. 1998 Nov;114(5):1309-15.

PMID:
9824007
29.

A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer.

Mehdi SA, Perry MC, Herndon JE 2nd, Crawford J, Young R, Graziano SL.

J Interferon Cytokine Res. 1998 Aug;18(8):623-7.

PMID:
9726444
30.

Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer.

Choy H, Safran H, Akerley W, Graziano SL, Bogart JA, Cole BF.

Clin Cancer Res. 1998 Aug;4(8):1931-6.

31.

Prognostic significance of Ki-67 immunostaining and symptoms in resected stage I and II non-small cell lung cancer.

Mehdi SA, Etzell JE, Newman NB, Weidner N, Kohman LJ, Graziano SL.

Lung Cancer. 1998 May;20(2):99-108.

PMID:
9711528
32.

Expression of neuron-specific enolase, chromogranin A, synaptophysin and Leu-7 in lung cancer cell lines.

Poola I, Graziano SL.

J Exp Clin Cancer Res. 1998 Jun;17(2):165-73.

PMID:
9700577
33.

The value of gallium imaging after therapy for Hodgkin's disease.

Bogart JA, Chung CT, Mariados NF, Vermont AI, Lemke SM, Grethlein S, Graziano SL.

Cancer. 1998 Feb 15;82(4):754-9.

PMID:
9477109
34.

Non-small cell lung cancer: clinical value of new biological predictors.

Graziano SL.

Lung Cancer. 1997 Jun;17 Suppl 1:S37-58. Review. No abstract available.

PMID:
9213302
35.

Paraneoplastic syndromes associated with small cell lung cancer.

Marchioli CC, Graziano SL.

Chest Surg Clin N Am. 1997 Feb;7(1):65-80. Review.

PMID:
9001756
36.

Blood group antigen A and flow cytometric analysis in resected early-stage non-small cell lung cancer.

Graziano SL, Tatum AH, Gonchoroff NJ, Newman NB, Kohman LJ.

Clin Cancer Res. 1997 Jan;3(1):87-93.

37.

A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study.

Graziano SL, Valone FH, Herndon JE 2nd, Crawford J, Richards F 2nd, Rege VB, Clamon G, Green MR.

Lung Cancer. 1996 Jun;14(2-3):315-29.

PMID:
8794413
38.

Preoperative evaluation of stage I and stage II non-small cell lung cancer.

Hatter J, Kohman LJ, Mosca RS, Graziano SL, Veit LJ, Coleman M.

Ann Thorac Surg. 1994 Dec;58(6):1738-41.

PMID:
7979746
39.

The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer.

Graziano SL, Tatum AH, Newman NB, Oler A, Kohman LJ, Veit LJ, Gamble GP, Coleman MJ, Barmada S, O'Lear S.

Cancer Res. 1994 Jun 1;54(11):2908-13.

40.

Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis.

Bass EB, Powe NR, Goodman SN, Graziano SL, Griffiths RI, Kickler TS, Wingard JR.

Bone Marrow Transplant. 1993 Sep;12(3):273-82.

PMID:
8241987
41.

A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.

Graziano SL, Herndon JE 2nd, Richards F 2nd, DiFino S, Modeas C, Duggan DB, Green MR.

Cancer. 1993 Jul 1;72(1):62-8.

PMID:
8389667
42.

Net costs from three perspectives of using low versus high osmolality contrast medium in diagnostic angiocardiography.

Powe NR, Davidoff AJ, Moore RD, Brinker JA, Anderson GF, Litt MR, Gopalan R, Graziano SL, Steinberg EP.

J Am Coll Cardiol. 1993 Jun;21(7):1701-9.

43.

Molecular implications of recurrent cytogenetic alterations in human small cell lung cancer.

Testa JR, Graziano SL.

Cancer Detect Prev. 1993;17(2):267-77.

PMID:
8402711
44.

Deficiency of acylpeptide hydrolase in small-cell lung carcinoma cell lines.

Scaloni A, Jones W, Pospischil M, Sassa S, Schneewind O, Popowicz AM, Bossa F, Graziano SL, Manning JM.

J Lab Clin Med. 1992 Oct;120(4):546-52.

PMID:
1328432
45.

Molecular characterization of a large homozygous deletion in the small cell lung cancer cell line U2020: a strategy for cloning the putative tumor suppressor gene.

Latif F, Tory K, Modi WS, Graziano SL, Gamble G, Douglas J, Heppell-Parton AC, Rabbitts PH, Zbar B, Lerman MI.

Genes Chromosomes Cancer. 1992 Sep;5(2):119-27.

PMID:
1381947
46.

Chromosome alterations in human small cell lung cancer: frequent involvement of 5q.

Miura I, Graziano SL, Cheng JQ, Doyle LA, Testa JR.

Cancer Res. 1992 Mar 1;52(5):1322-8.

47.

Nephrotoxicity of low osmolality contrast media versus high osmolality media.

Steinberg EP, Moore RD, Brinker JA, Fishman EK, Powe NR, Graziano SL, Gopalan R.

Invest Radiol. 1991 Nov;26 Suppl 1:S86; discussion S88-91. No abstract available.

PMID:
1808157
48.

Involvement of the RAF1 locus, at band 3p25, in the 3p deletion of small-cell lung cancer.

Graziano SL, Pfeifer AM, Testa JR, Mark GE, Johnson BE, Hallinan EJ, Pettengill OS, Sorenson GD, Tatum AH, Brauch H, et al.

Genes Chromosomes Cancer. 1991 Jul;3(4):283-93.

PMID:
1683566
49.

Cisplatin-carboplatin therapy in extensive non-small cell lung cancer: a Cancer and Leukemia Group B study.

Kreisman H, Goutsou M, Modeas C, Graziano SL, Costanza ME, Green MR.

Eur J Cancer. 1990;26(10):1057-60.

PMID:
2177346
50.

Phase II trial of etoposide and cisplatin for refractory small cell lung cancer: a Cancer and Leukemia Group B Study.

Graziano SL, Lee K, Propert KJ, Tinsley R, Hayes DM, Green M, Comis RL.

Med Pediatr Oncol. 1990;18(1):22-6. Review.

PMID:
2152956

Supplemental Content

Loading ...
Support Center